Dr Reddys gets EIR from USFDA for manufacturing plants at Duvvada

The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at the formulations manufacturing plants at Duvvada Visakhapatnam, Dr Reddy's Laboratories said in a regulatory filing.

New Delhi: Dr Reddy's Laboratories on Thursday said it has received establishment inspection report (EIR) from the US health regulator for its Visakhapatnam facility in Andhra Pradesh.

The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at the formulations manufacturing plants at Duvvada Visakhapatnam, Dr Reddy's Laboratories said in a regulatory filing.

Read Also: Dr Reddys unveils a generic version of Zyban ER tablets in the US

The inspection of the two facilities were completed by the USFDA on June 21 this year, it added.

"We have now received an EIR from the USFDA, indicating closure of this audit," the company said.

The USFDA gives EIR on closure of inspection of an establishment that is the subject of USFDA or USFDA-contracted inspection.

Read Also: Dr Reddys gets 8 USFDA observations for Duvvada facility in Andhra Pradesh